BNET Industries
Market Cap:$89.2M
Last Fiscal Year Sales:$7.1M
- Public
- US
Dow Jones Description
Neoprobe Corporation is focused on developing and commercializing innovative biomedical products that meet the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. Our primary area of focus is in improving cancer surgery outcomes by using our market-leading gamma detection devices in combination with radiopharmaceutical agents also referred to as "tracing" or "targeting" agents. We have also recently formed another majority-owned subsidiary, Cira Biosciences, Inc., to explore the development and commercialization of an activated cellular therapy technology that has shown promising early stage patient-specific treatment potential in oncology, viral (HIV/AIDS and hepatitis) and autoimmune diseases.
CEO and President
David C. BuppNumber of Employees 25
Peer Companies
NAICS Code Surgical and Medical Instrument Manufacturing: 339112
Recent Events
-
Neoprobe books $25 million loss in Q3
-
Laureate Pharma to Manufacture Neoprobe's MAb Product
-
Neoprobe finds manufacturer for Rigscan
-
Laureate Pharma and Neoprobe Corporation Announce Manufacturing Alliance - Laureate to Manufacture Neoprobe's RIGScanR CR...
-
Neoprobe continues losses in Q2
-
Neoprobe Announces Second Quarter Results
-
Neoprobe to Receive $3.5 Million from Montaur Warrant Exercise RIGS Biologic Development Initiative Commenced
-
Taglich Brothers Initiates Coverage of Neoprobe Corporation
News & Analysis
Filter by
neoprobe corp. - All News and Analysis
Neoprobe Letter to the Shareholders
DUBLIN, Ohio -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today released the text of its annual Letter to Stockholders from Neoprobe Chairman, Carl J. Aschinger, Jr., and President and CEO, David C. Bupp. The letter highlights Neoprobe's business and...
Neoprobe Announces Extension of Marketing Agreement with Ethicon Endo-Surgery, Inc
DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced the extension of its marketing and distribution agreement with Cincinnati-based Ethicon Endo-Surgery, Inc. The amendment extends the rights for Ethicon Endo-Surgery to promote and sell the neo2000[R] gamma detection systems...
Neoprobe Secures $6 Million Commitment from Fusion Capital
DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today that it signed an agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor, for the purchase of up to $6 million in common stock. Sales of common stock...
Neoprobe Announces Renewal of Marketing Agreement With Ethicon Endo-Surgery, Inc
DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it had received notification of the renewal its Marketing and Distribution Agreement with Ethicon Endo-Surgery, Inc., through December 2008. Ethicon Endo-Surgery has distributed the Company's neo2000R gamma detection system...
Neoprobe Receives Cellular Therapy Technology Assessment; Positive Technology Review and Clinical Recommendations Received
DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its subsidiary, CIRA Biosciences, Inc. CIRA Bio, has received an independent technology assessment report on its activated cellular therapy ACT technology. The recently completed assessment was performed by the...
Neoprobe Provides Business Update
Business Editors & Health/Medical Writers DUBLIN, Ohio--BW HealthWire--Feb. 22, 2001 Neoprobe Corporation (OTCBB:NEOP) today provided an update to shareholders. In the form of a report to shareholders, Neoprobe president and CEO, David Bupp, said, "We are pleased to report that 2000 was a very positive year for...
Neoprobe Ranked Number 389 Fastest-Growing Technology Company in North America on Deloitte & Touche Technology Fast 500
Business Editors, Health/Medical Writers DUBLIN, Ohio--BW HealthWire--Nov. 16, 2000 Neoprobe Corporation (OTCBB:NEOP) today announced that it ranked Number 389 on the Deloitte & Touche Technology Fast 500, a ranking of the 500 fastest-growing technology companies in North America. Rankings are based on five-year percentage revenue growth from...
Neoprobe and U.S. Surgical Terminate Marketing Agreement
DUBLIN, Ohio--BW HealthWire--Oct. 13, 1997--Neoprobe Corporation (Nasdaq NMS: NEOP) and United States Surgical Corporation (NYSE: USS) today announced that the companies have terminated their marketing agreement. Leon C. Hirsch, chairman and CEO of USS, said, "USS will honor all customer commitments and will work out an orderly...
Neoprobe's product marketing application formally accepted for review by European authorities
DUBLIN, Ohio--BUSINESS WIRE--July 16, 1996--Neoprobe Corp. (NASDAQ NMS: NEOP, NEOPW) today announced that its marketing application for its first cancer detection product, RIGScanR CR49, was formally accepted for review by the European regulatory authorities"This acceptance by the authorities in Europe was completed after an extensive and comprehensive review of our...
Montgomery Securities Initiates Coverage of Neoprobe Corporation, Nasdaq:NEOP, with a BUY Rating
SAN FRANCISCO--BUSINESS WIRE--April 18, 1996--Montgomery Securities Analyst Dr. Len Yaffe has initiated coverage of Neoprobe Corp. (NASDAQ: NEOP) with a BUY rating.Dr. Yaffe expects the company to achieve profitability in the second half of 1998, earning $0.70, per share in Fiscal Year December 1999 and $1.70, per share in Fiscal...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| David C. Bupp | CEO and President |
| Brent L. Larson | Vice President Finance and Cfo |
| Anthony K. Blair | Vice President, Manufacturing Operations |
| Carl M. Bosch | Vice President, Research and Development |
| Douglas L. Rash | Vice President, Marketing |
| Rodger A. Brown | Vice President |
| Richard Orahood | Neoprobe's Medical Director |
| John S. Christie | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Carl J. Aschinger | Chairman of the Board of Directors |
| Fred B. Miller | Chairman |
| Julius R. Krevans | Chairman |
| Kirby I. Bland | Chairman |
| Gordon A. Troup | Board of Directors |
| J Carl Jr | Board of Directors |
| J. Frank Whitley Jr. | Board of Directors |
| Nancy E. Katz | Board of Directors |
| Owen E. Johnson | Board of Directors |
| Reuven Avital | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | CEO and President | Current |
| Neoprobe Corporation | Board of Directors | Current |
| Neoprobe Corporation | President and Director | Former |
| Ohio Wesleyan University | B.A. Degree In Economics | Former |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Vice President Finance and Cfo | Current |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Vice President, Manufacturing Operations | Current |
| Enpath Medical, Inc. | Vice President, Manufacturing Operations | Former |
| Fisher Body Corporation | Former | |
| Cleveland State University | B.B.A. Degree In Management | Former |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Vice President, Research and Development | Current |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Vice President, Marketing | Current |
| Neoprobe Corporation | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Neoprobe's Medical Director | Current |
| Organization | Position | Status |
|---|---|---|
| Worthington Industries, Inc. | President | Current |
| Neoprobe Corporation | Secretary | Current |
| Crane Group Limited | Advisory Board Member | Current |
| The Fishel Company Inc. | Advisory Board Member | Current |
| Bank One, N.A. | Advisory Board Member | Current |
| Miami University | Board of Directors | Current |
| Worthington Cylinder Corporation | President | Former |
| JMAC Inc. | President | Former |
| Worthington Industries, Inc. | Chief Financial Officer | Current |
| Worthington Industries, Inc. | Founder | Former |
| SPX Corporation | Officer | Former |
| Worthington Industries, Inc. | Chairman Emeritus | Former |
| SPX Corporation | Director | Former |
| Neoprobe Corporation | Secretary | Former |
| Franklin University | Board Member | Former |
| Worthington Industries, Inc. | Director | Current |
| Miami University | Bachelor of Science Degree In Business Administration | Former |
Array
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Chairman of the Board of Directors | Current |
| Csc Worldwide | Chairman | Current |
| Neoprobe Corporation | Board of Directors | Current |
| Pinnacle Data Systems, Inc. | Board of Directors | Current |
Fred B. Miller has served as a director of our Company since January 2002. Mr. Miller serves as Chairman of the Audit committee. Mr. Miller is the President and Chief Operating Officer of Seicon, Limited, a privately held company that specializes in developing, applying and licensing technology to reduce seismic and mechanically induced vibration. Mr. Miller also serves on the boards of two other privately-held companies. Until his retirement in 1995, Mr. Miller had been with Price Waterhouse LLP since 1962. Mr. Miller is a Certified Public Accountant, a member of the American Institute of Certified Public Accountants (AICPA), a past member of the Council of the AICPA and a member and past president of the Ohio Society of Certified Public Accountants. He also has served on the boards or advisory committees of several universities and not-for-profit organizations. Mr. Miller has a B.S. degree in Accounting from the Ohio State University.
| Organization | Position | Status |
|---|---|---|
| American Institute of Certified Public Accountants | Member | Current |
| Neoprobe Corporation | Chairman | Current |
| Neoprobe Corporation | Board of Directors | Current |
| American Institute of Certified Public Accountants | Member | Current |
| The Ohio State University | B.S. Degree In Accounting | Former |
Company since May 1994 and as Chairman of the Board of Directors of our Company since February 1999. Dr. Krevans served as Chancellor of the University of California, San Francisco from July 1982 until May 1993. Prior to his appointment as Chancellor, Dr. Krevans served as a Professor of Medicine and Dean of the School of Medicine at the University of California, San Francisco from 1971 to 1982. Dr. Krevans is a member of the Institute of Medicine, National Academy of Sciences, and led its committee for the National Research Agenda on Aging until 1991. Dr. Krevans also serves on the Board of Directors and the compensation committee of the Board of Directors of Calypte Biomedical corporation (Calypte), a publicly held corporation. Dr.Krevans has a B.S. degree and a M.D. degree, both from New York University.
| Organization | Position | Status |
|---|---|---|
| National Academy of Sciences | Member | Current |
| Neoprobe Corporation | Chairman | Current |
| Neoprobe Corporation | Board of Directors | Current |
| Calypte Biomedical Corporation | Board of Directors | Current |
| University of California, San Francisco | Director of International Medical Care | Former |
| University of California, San Francisco | Professor of Medicine | Former |
| New York University | M.D. Degree | Former |
| New York University | B.S. Degree | Former |
| Johns Hopkins University School of Medicine | residency in Medicine | Former |
Kirby I. Bland, M.D. has served as a director of our Company since May 2004. Dr. Bland currently serves as Professor and Chairman and Fay Fletcher Kerner Professor and Chairman Department of Surgery of the University of Alabama at Birmingham (UAB) School of Medicine since 1999 and 2002, respectively, Deputy Director of the UAB Comprehensive Cancer Center since 2000 and Senior Scientist, Division of Human Gene Therapy, UAB School of Medicine since 2001. Prior to his appointments at UAB, Dr. Bland was J. Murry Breadsley Professor and Chairman, Professor of Medical Science, Department of Surgery and Director, Brown University Integrated Program in Surgery at Brown University School of Medicine from 1993 to 1999. Prior to his appointments at Brown University, Dr. Bland was Professor and Associate Chairman, Department of Surgery, University of Florida College of Medicine from 1983 to 1993 and Associate Director of Clinical Research at the University of Florida Cancer Center from 1991 to 1993. Dr. Bland held a number of medical staff positions at the University of Louisville, School of Medicine from 1977 to 1983 and at M. D. Anderson Hospital and Tumor Institute from 1976 to 1977. Dr. Bland is a member of the Board of Governors of the American College of Surgeons (ACS), a member of the ACS' Advisory Committee, Oncology Group (ACOSOG), a member of the ACS' American Joint Committee on Cancer Task Force and serves as Chairman of the ACS' Breast Disease Site Committee, COC. Dr. Bland is a past President of the Society of Surgical Oncology. Dr. Bland received his B.S. in Chemistry/Biology from Auburn University and a M.D. degree from the University of Alabama, Medical College of Alabama.
| Organization | Position | Status |
|---|---|---|
| The University of Alabama at Birmingham | Professor | Current |
| The University of Alabama at Birmingham | Chairman | Current |
| Neoprobe Corporation | Chairman | Current |
| Neoprobe Corporation | Director | Current |
| The Oncology Group | Board of Directors | Current |
| The Oncology Group | Member | Current |
| Society of Surgical Oncology | President | Former |
| University of Florida | Director of Clinical Research | Former |
| University of Florida | Professor | Former |
| University of Louisville | Former | |
| University of Florida | Chairman | Former |
| The University of Alabama | M.D. Degree | Former |
| Auburn University | B.S. In Chemistry, Biology | Former |
Gordon A. Troup, age 58, has served as a director of our company since July 2008, Mr. Troup served as President of the Nuclear Pharmacy Services business at Cardinal Health, Inc. (Cardinal), a multinational medical products and services company, from January 2003 until his retirement in December 2007. Mr. Troup joined Cardinal in 1990 and was appointed Group President of Pharmaceutical Distribution and Specialty Distribution Services in 1999. Prior to joining Cardinal Mr. Troup was employed for 10 years by American Hospital Supply Corporation and 3 years by Zellerbach Paper, a Mead Company. Mr. Troup has a B.S. degree in Business Management from San Diego State University. Mr. Troup is the member of several national healthcare trade organizations and is active in a number of not-for-profit organizations.
| Organization | Position | Status |
|---|---|---|
| The Cardinal | Current | |
| Neoprobe Corporation | Board of Directors | Current |
| Cardinal Health, Inc. | Executive Vice President | Former |
| Nuclear Pharmacy Services | President & Executive Vice President | Former |
| San Diego State University | B.S. Degree In Business Management | Former |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Board of Directors | Current |
| The Dow Chemical Company | Director of Mergers, Acquisitions and Licensing | Former |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Neoprobe Corporation | Board of Directors | Current |
| Ohio.Com | Vice President | Former |
| Ohio.Com | Senior Medical Director of United Healthcare | Former |
Executive News
-
Neoprobe Announces Annual Meeting Results
Industry Transcripts by Seeking Alpha
-
Hansen Medical, Inc. Q3 2009 Earnings Call Transcript
on Dec 18, 2009about HNSN
-
Synergetics USA, Inc. F1Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about SURG
-
Cantel Medical Corp. F1Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 09, 2009about CMN
-
The Cooper Companies, Inc. F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 08, 2009about COO
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call Transcript
on Nov 24, 2009about MDT


